AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Clinical trials for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) explained in plain language.
Never miss a new study
Get alerted when new AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) trials appear
Sign up with your email to follow new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug slow kidney loss in inherited cystic disease?
Disease control CompletedThis study tested whether lanreotide, a drug that affects certain hormones, can slow the loss of kidney function in people with autosomal dominant polycystic kidney disease (ADPKD). The trial included 159 adults with moderate kidney damage and measured their kidney function over …
Matched conditions: AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Drug interaction study: VX-407 and oral contraceptives
Knowledge-focused CompletedThis completed Phase 1 study looked at how a new drug called VX-407 changes the levels of various birth control pills in the body. 74 healthy adults participated to measure drug levels and check safety. The results will help doctors understand if birth control pills work properly…
Matched conditions: AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Phase: PHASE1 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Knowledge-focused
Last updated May 17, 2026 09:50 UTC
-
Thousands with kidney disease tracked to uncover hidden clues of decline
Knowledge-focused CompletedThis study followed more than 3,400 people with autosomal dominant polycystic kidney disease (ADPKD) to learn how the disease gets worse over time. Researchers measured kidney size and tracked symptoms, quality of life, and healthcare costs. The goal was to find early signs that …
Matched conditions: AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 09:43 UTC
-
First safety check for new ADPKD drug candidate
Knowledge-focused CompletedThis early-stage study tested the safety and how the body handles VX-407 in 32 healthy adults. Participants received either the drug or a placebo to check for side effects and measure drug levels in the blood. The results will help decide if VX-407 should move into future trials …
Matched conditions: AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Phase: PHASE1 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC
-
Real-world data reveals how a kidney drug impacts daily life and delays dialysis
Knowledge-focused CompletedThis study followed 530 adults with autosomal dominant polycystic kidney disease (ADPKD) who were already taking tolvaptan (JINARC™) as part of their routine care. Researchers measured how the drug affected patients' quality of life, pain, and ability to work, as well as how long…
Matched conditions: AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Sponsor: Otsuka Canada Pharmaceutical Inc. • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC
-
Bergamo gene clue: new mutation found in kidney disease patients
Knowledge-focused CompletedThis study examined 10 people with autosomal dominant polycystic kidney disease (ADPKD) to see if a specific missing piece in the PKD2 gene is shared among families in the Bergamo area. Researchers collected medical histories and DNA samples to understand how this gene change aff…
Matched conditions: AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated May 12, 2026 13:40 UTC